| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_880fdd58fb74dc19b8025af4de7153af |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 |
| filingDate |
2013-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c69fc7600d17cab5ecf7a7678cd024c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53b206a2dbbaa6be85fe31cbe2779258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eab97c73791dccfac175495adb98bee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77df78ffe3a1680e47195c94323a57f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85d4862f8c35b8909bb50c133e01172f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdd71a72d7dcb0780c3a30b2fdc66858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_424ea2d2275f455e37d981c698ec20c4 |
| publicationDate |
2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9580490-B2 |
| titleOfInvention |
Uses of modified human tumor necrosis factor receptor-1 polypeptide |
| abstract |
The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNFα neutralizing activity, and inhibits TNFα activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome. |
| priorityDate |
2012-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |